The study aims to identify which environmental factors, if improved, will yield the greatest benefits for children with disabilities and their families. This knowledge will inform EU policy in the health, educational and social sectors and generate protocols to optimise outcomes

Inclusion criteria

Children with cerebral palsy (local registers) aged 8-12 years at the beginning of the study

Last update : 01/01/2020

Voir

View

ANRS CO8 APROCO-COPILOTE - Cohort of HIV-infected patients who began treatment with protease inhibitor in 1997-1999. Follow-up over 4 years on the long-term effects linked with adherence and tolerance (COPILOT).

Head : Leport Catherine, LABORATOIRE DE RECHERHE EN PATHOLOGIE INFECTIEUSE

Version 3

Voir

View

Overview

179

Last update : 01/01/2019

ANRS CO8 APROCO-COPILOTE - Cohort of HIV-infected patients who began treatment with protease inhibitor in 1997-1999. Follow-up over 4 years on the long-term effects linked with adherence and tolerance (COPILOT).

Head : Leport Catherine, LABORATOIRE DE RECHERHE EN PATHOLOGIE INFECTIEUSE

Main objective

General objective: To investigate determinants for long-term effects of adherence and tolerance to highly active antiretroviral drugs, in relation to patients infected with HIV-1 who were treated for the first time under a protease inhibitor in 1997-99. Secondary objectives: - to determine the part that host genetic polymorphisms play in the progression of the infection and onset of serious adverse events - to investigate viral load and antiretroviral resistance in plasma cell compartments in relation to antiretroviral concentrations over time.

Inclusion criteria

Patients included in the APROCO cohort (adults infected with HIV-1 at first prescription of protease inhibitor in 1997-99), monitored for four years in APROCO after initial enrolment, monitored by voluntary services in order to participate in extended follow-up, having given their written consent.

Last update : 01/01/2019

Voir

View

DECLIC - Description of the profile of hypertensive patients treated with calcium channel blokers

Head : Millet véronique, Pfizer

Version 1

Voir

View

Overview

180

Last update : 01/01/2018

DECLIC - Description of the profile of hypertensive patients treated with calcium channel blokers

Head : Millet véronique, Pfizer

Main objective

Describe the profile and the care for hypertensive patients treated with calcium channel blockers and their distribution according to the level of the cardio-vascular risk as defined by HAS (French National Authority for Health) 2005.
- Describe the distribution of the risk factors according to sub-groups of age.
- Describe the profile of hypertensive patients on calcium channel blockers according to blood pressure control.
- Describe the therapeutic strategy when the high blood pressure is not controlled.

Inclusion criteria

Patient over the age of 18 years.
- Patient seen through routine liberal medical practice, regardless of the reason for consultation.
- Hypertensive patient whether or not balanced, treated with calcium channel blockers in monotherapy or in association.
- Patient informed of the objectives of the survey.

Last update : 01/01/2018

Voir

View

Export to XML

Export to PDF

Export to CSV

- Cohort of Swimmers: Health Effects of Exposure to Water Disinfection By-Products

Main objective

Inclusion criteria

TRACY - French cohort of uranium cycle workers

Main objective

Inclusion criteria

EPIMART - Cross-sectional Study on Epileptic Patients Living in Martinique

Main objective

Inclusion criteria

SPARCLE - Longitudinal study on Children with Cerebral Palsy Living in Europe

Main objective

Inclusion criteria

ANRS CO8 APROCO-COPILOTE - Cohort of HIV-infected patients who began treatment with protease inhibitor in 1997-1999. Follow-up over 4 years on the long-term effects linked with adherence and tolerance (COPILOT).

Main objective

Inclusion criteria

DECLIC - Description of the profile of hypertensive patients treated with calcium channel blokers

Main objective

Inclusion criteria

Please wait...